Stifel on Viking Therapeutic (VKTX) Sell-Off: 'an over-reaction to the successful Ph.2 VENTURE-Oral (13-week) outcome'
Tweet Send to a Friend
Stifel analyst Samimy Annabel reiterated a Buy rating and $95.00 price target on Viking Therapeutic (NASDAQ: VKTX)The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
